SCHEMBL12810046

SCHEMBL12810046

Cc1cnc2cc(Cl)ccc2c1O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
CYP3A4 P08684 2/20 0.55
TLR8 Q9NR97 1/20 0.49
POLB P06746 1/20 0.47
NR4A2 P43354 3/20 0.43
SOS2 Q07890 1/20 0.43
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
PPARG P37231 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NR2E3 Q9Y5X4 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 1/20 0.39
MPO P05164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2519868 0.81 ALDH1A1 (0.54) ALDH1A1CYP3A4TLR8POLBNR4A2
SCHEMBL18283411 0.81 NR4A2 (0.46) ALDH1A1CYP3A4TLR8POLBNR4A2
SCHEMBL5765299 0.80 NR4A2 (0.58) ALDH1A1CYP3A4TLR8NR4A2SOS2
SCHEMBL15111036 0.79 NR4A2 (0.43) ALDH1A1CYP3A4TLR8POLBNR4A2
SCHEMBL18283482 0.79 NR4A2 (0.43) ALDH1A1CYP3A4TLR8POLBNR4A2
SCHEMBL28467228 0.78 GAK (0.46) ALDH1A1CYP3A4POLBMAPTRXFP1
SCHEMBL11704085 0.77 ALDH1A1 (0.47) ALDH1A1CYP3A4TLR8POLBNR4A2
SCHEMBL11062749 0.76 CYP3A4 (0.43) ALDH1A1CYP3A4TLR8NR4A2SOS2
SCHEMBL25953825 0.76 TLR8 (0.51) ALDH1A1TLR8MPO
SCHEMBL15801275 0.75 PARP1 (0.45) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647677-B2 Analogues of hydroxychloroquine (HCQ) without retinal toxicity INOVIEM SCIENTIFIC (FR) 2020-05-12 US disclosed
EP-1807421-B1 2-AMIDO-4-PHENYLTHIAZOLE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2011-03-16 EP disclosed
US-7598392-B2 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2009-10-06 US disclosed
US-7598392-B2 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof SANOFI-AVENTIS (FR) 2009-10-06 US disclosed
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2007-11-08 US disclosed
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647677-B2 Analogues of hydroxychloroquine (HCQ) without retinal toxicity SSB, UACA, XPA ALDH1A1 1358/4885CYP3A4 1361/4885TLR8 1443/4885
US-20070259847-A1 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof PKD2, TPMT, PKD1 ALDH1A1 950/4885CYP3A4 45/4885TLR8 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.